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Background. Cystic ﬁbrosis (CF) patients are in increased risk of osteoporosis. We aimed to determine the osteoporosis prevalence
in an adult CF cohort and investigate calcium metabolic parameters and clinical status’ association with bone mineral density
evaluated by dual X-ray absorptiometry scan. Methods. We performed a cross section database study of adults at a tertiary CF
Center. Z scores were applied for patients< 50 years of age and T scores for patients> 50 years of age. Results. One hundred
twenty-ﬁve patients were included. Compared to nonosteoporotic patients, osteoporotic patients (15%) had signiﬁcantly lower
percent predicted forced expiratory volume in 1 second (ppFEV1), lower body mass index, higher frequency of CF-related
diabetes and chronic lung infection, and higher high-sensitive C-reactive protein and glycated hemoglobin levels. Vitamin D
was not associated with any outcome. In multivariate analyses, only ppFEV1 and female gender were independently associated
with Z scores. Conclusions. Osteoporosis in CF occurs with deteriorating clinical status while the role of calcium metabolism
seems minor. Gender speciﬁc and dysglycemic impact on bone status should be investigated further.
1. Introduction
As treatments for cystic ﬁbrosis have improved, the median
life expectancy has increased over the last decades [1]. How-
ever, as lifespan increases so does the risk of comorbidities.
One of these is osteoporosis, and CF patients have increased
risk of osteoporosis compared to age-matched controls [2, 3].
Another frequent feature of CF is vitamin D deﬁciency [2, 3].
A silent disease, osteoporosis has no clinical manifesta-
tions but the consequence—osteoporotic fractures—does.
Osteoporotic fractures may have severe consequences for
CF patients. Low-impact fractures, for example, costa frac-
tures from coughing may worsen their pulmonary condition
as reduced coughing, due to thoracic pains, will lead to spu-
tum stagnation and reduced airway clearance. This will favor
the conditions for bacterial growth, ultimately leading to pul-
monary exacerbation [4]. Furthermore, vertebral fractures
can lead to anatomic changes of the thorax, which may
impede or even rule out lung transplantation [2, 3, 5, 6].
Factors such as calciummetabolic alterations, malabsorp-
tion, delayed puberty, chronic inﬂammation, and many other
conditions associated with CF [2, 7, 8] can prevent patients
from achieving peak bone mass equal to their healthy peers
and increase bone loss in adulthood.
The aim of the study was to determine the prevalence of
osteoporosis in a cohort of well-treated CF adults and inves-
tigate clinical and calcium metabolic parameter’s association
with BMD.
2. Methods
We performed a cross section study of adults at the Copenha-
gen CF Center.
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All CF patients are followed monthly with assessment of
clinical status (lung function parameters, body mass index
(BMI), and sputummicrobiology) at the CF outpatient clinic.
An annual review is performed including extensive bio-
chemical evaluation. Clinical data and prescribed medica-
tions are prospectively registered in patient records and
the CF Center database.
Patients are routinely supplemented with fat-soluble
vitamins A, D (D3) (2400 International Units (IU) chole-
calciferol), E, and K.
Study inclusion criteria were patients with a conﬁrmed
CF diagnosis by genotyping and/or sweat test aged ≥20 years
attending the Copenhagen CF Center regularly (at least 4
times a year), with at least one DXA scan between 2010 and
2015. Patients with a history of solid organ transplantation
were excluded.
The following data were extracted from the CF database:
weight, height, BMI (average BMI within the same year as
DXA and blood samples were performed), CF genotype, gen-
der, and age. Further, information about chronic bacterial
lung infection, pancreas insuﬃciency, CF-related diabetes
(CFRD), and lung function (ppFEV1) [9, 10] were obtained.
From medical records, information regarding additional
vitamin D3 beyond routine supplementation, contraceptives,
inhaled steroids, PPI use, and bone antiresorptive treatment
(bisphosphonates) were obtained.
2.1. Bone Densitometry. Bone mineral density (BMD) was
determined with DXA scan (Lunar Prodigy Pro, GE Health-
care, Madison, WI, USA). BMD was measured in the lumbar
spine (L2–L4) and in the right and left femoral neck and tro-
chanter regions. All measurements were performed by
trained technicians and reviewed by trained physicians, and
the same scanner was used for all measurements. Results
were expressed as BMD (g/cm2), T scores (the number of
standard deviations a given BMD value diﬀers from the mean
value of young healthy adults), and Z scores (the number of
standard deviations a given BMD value diﬀers from the mean
of healthy age- and gender-matched controls). Scores were
calculated with a German normal reference material pro-
vided by the manufacturer. International Society for Clinical
Densitometry (ISCD) criteria for younger males< 50 years of
age and premenopausal females were applied, deﬁning Z
scores<−2 as BMD below expected range for age and Z
scores≥−2 as BMD within expected range for age [11],
which was then deﬁned as osteoporosis and BMD within
the normal range, respectively. Participants above 50 years
of age were grouped according to WHO criteria deﬁnitions
[12] with T scores≤−2.5 deﬁning osteoporosis. Left femur
was used in analyses unless otherwise stated.
2.2. Blood Tests. From an extended blood panel drawn the
same year as DXA scan was performed, the following
parameters were available: vitamin D (25OHD) (vitamin
D3+ vitamin D2), alkaline liver transaminase (ALT), alka-
line phosphatase, hemoglobin A1c (hbA1c), creatinine,
thyroid-stimulating hormone (TSH), total immunoglobulin
G (IgG), albumin, magnesium (Mg2+), and phosphate
(PH−). Follicle-stimulating hormone (FSH), luteinizing
hormone (LH), total testosterone, total estradiol, parathyroid
hormone (PTH), total calcium, and high-sensitive C-reactive
protein (hsCRP) were analyzed from frozen serum samples
collected at the same sample date as the extended blood
panel. All frozen samples were stored at −80°C until analysis.
Total testosterone, total estradiol, FSH, LH, and PTH were
measured by electrochemiluminescence immunoassays
(ECLIA) (Cobas, Roche, Switzerland). Coeﬃcient of varia-
tion for these was PTH 7%, FSH and LH 7%, total testoster-
one 6% and 5% at levels 3 nmol/l and 35nmol/l, respectively,
and total estradiol 11% and 7% at levels 0.2 nmol/l and
2.5 nmol/l, respectively.
2.3. Lung Function Test. Lung function tests were performed
at every outpatient visit according to American Thoracic
Society/European Respiratory Society (ATS/ERS) guide-
lines [9, 10] using Jaeger Master Screen Pro (CareFusion,
Hochberg, Germany). For the study, mean ppFEV1 of all
measurements within the year of DXA scan was calculated
and used.
2.4. Statistical Analysis. Descriptive statistics are presented as
median and interquartile range (IQR), mean and standard
deviation (SD) or percentage (%) as appropriate. ANOVA,
parametric/nonparametric T-test according to distribution,
or chi-square test were used to compare groups (vitamin D
levels, men versus women, normal BMD versus osteoporo-
sis). When groups were very unequal in sample size, Welch
T-test was used. Univariate regression analysis was per-
formed to evaluate associations between bone measurements
and factors. Nonnormal distributed data were log10 trans-
formed or square rooted. Finally, a predeﬁned multivariate
linear regression (MLR) model was performed for both T
and Z scores containing the variables gender, ppFEV1, BMI,
chronic infection (no/yes), hsCRP, 25OHD, and estradiol.
For regression analyses, both Z and T scores were used as
much previous literature in adults is based on T scores. All
analyses were performed with SPSS ver. 22. A p value< 0.05
was considered statistically signiﬁcant.
The study protocol was approved by the Local Ethics
Committee (H-15008060) and Local Data Protection Agency
(RH-2015-186, I-suite number 04107).
3. Results
Of 172 nonlung transplanted patients≥ 20 years of age, 125
patients fulﬁlled the inclusion criteria and were included.
Baseline characteristics are depicted in Table 1. Ten
patients were scanned in 2012, 31 patients in 2013, 53
patients in 2014, and 31 patients in 2015.
4. Vitamin D
The median (IQR) 25OHD level in the cohort was 49.5 nmol/
l (32–71) (Table 2). Twenty-four patients (19%) had 25OHD
levels≥ 75 nmol/l. Of those, twelve (50%) received additional
vitamin D3 (mean 400 IU daily, IQR: 400 IU–800 IU) in addi-
tion to routine supplementation of 2400 IU daily. In total,
forty seven patients were prescribed additional D3 substitu-
tion besides routine supplementation but there was no
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signiﬁcant diﬀerence in 25OHD levels between receivers
and nonreceivers of extra D3, mean levels 51 nmol/l and
53nmol/l, p = 0 7, respectively. Overall, the 25OHD level
was signiﬁcantly higher in patients, who had their
25OHD levels measured during May–October than during
the winter months (mean levels 59.6 nmol/l versus
47.1 nmol/l, p = 0 02). There was no seasonal variation in
other calcium metabolic parameters, that is, PTH, total
calcium, Mg2+, or PH− (Figure 1).
Patients were subgrouped according to 25OHD levels as
deﬁcient< 25 nmol/l, insuﬃcient> 25–50 nmol/l, and reple-
te> 50nmol/l. There was no statistical signiﬁcant diﬀerence
in baseline characteristics. Parathyroid hormone was signiﬁ-
cantly higher in the deﬁciency group compared to the insuf-
ﬁcient group (mean diﬀerence 1.35, 95% CI 0.27–2.43,
p = 0 006) and replete group (mean diﬀerence 1.43, 95% CI
0.52–2.34, p = 0 001). Total calcium levels did not diﬀer
between groups, but PH− was signiﬁcantly lower in the deﬁ-
ciency group compared to the replete group (mean diﬀerence
between groups 0.13, 95% CI: 0.03–0.23, p = 0 005). How-
ever, both mean PTH values and mean PH− values were
within normal range in all vitamin D groups (Table 3).
Neither Mg2+ nor alkaline phosphatase was signiﬁcantly dif-
ferent between groups.
4.1. Hormones. Hormones were analyzed gender speciﬁc.
Amongst women, it was not possible to retrieve data
regarding menstrual cycle, possible amenorrhea, or peri/
postmenopausal stage. Six women were according to
medical records taking oral contraceptives and excluded
from further hormonal analyses. Hormonal levels are
depicted in Table 4. The majority of women below the
age of 50 had estradiol levels below 0.5 nmol/l.
In men, median estradiol level was 0.1 nmol/l (0.09–
0.23). Overall median testosterone for men< 50 years of
age was 2.6 (0.73–13.46).
4.2. Bone Status Assessment. The overall DXA scan results are
depicted in Table 1. Nineteen patients (15%) had osteoporo-
sis, ﬁfteen patients (12%) had Z scores below the expected
range for age (Z scores<−2), and four patients had T
scores≤−2.5 and were above 50 years of age. Mean Z scores
of the overall cohort were signiﬁcantly lower compared to
the mean healthy age-matched general population and mean
diﬀerence between groups was −0.748 (95% CI: −0.95 to
−0.55), p < 0 001. Patients homozygous for the F508del had
signiﬁcantly lower BMD than nonhomozygous patients. For
femoral BMD, mean diﬀerence between groups was −0.09
(95% CI: −0.16 to −0.01), p = 0 03, and for lumbar BMD,
mean diﬀerence between groups was −0.07 (95% CI: −0.13
to −0.01), p = 0 02.
Compared to the group with BMD values within the
normal range, osteoporotic patients had signiﬁcantly lower
average ppFEV1 (p < 0 001), BMI (p < 0 001), and albumin
(p = 0 01), but there was no signiﬁcant diﬀerence in age
(34 years versus 31 years, p = 0 19) or gender distribution
in groups (p = 0 16) (Table 5).
The osteoporosis group was more frequently chronically
infected (p = 0 02) and had higher hsCRP levels (p = 0 04),
but there was no diﬀerence in IgG between groups.
Patients with osteoporosis also had a higher frequency (
p = 0 03) but not a longer duration of CFRD (p = 0 06), and
hbA1c was signiﬁcantly higher compared to the group with
BMD values within the normal range (p < 0 001).
ALT was higher among patients with osteoporosis, but
no other calcium metabolic-, liver-, and kidney parameters
diﬀered between the groups (Table 2).
There was no diﬀerence in frequency of PPI or steroid IH
usage between groups (Table 5).
Estradiol levels were signiﬁcantly lower in osteoporotic
women compared to women with BMD within the normal
range (Table 4). In men, median estradiol levels were at the
lower limit of the reference interval (0.09 nmol/l) for both
groups; no sex hormone levels diﬀered between osteoporotic
and nonosteoporotic men.
4.3. Regression Analyses. Univariate associations between
bone status and clinical and paraclinical parameters are
presented in Table 6. In multivariate regression analysis
(MLR), femoral Z and T scores were independently associ-
ated with ppFEV1 and chronic infection. Spine Z and T
scores were independently associated with ppFEV1,
chronic infection, and female gender, and spine T score
was also with BMI (Table 7).
5. Discussion
In a well-treated and closely monitored cohort of adult CF
patients, we found that 15% had osteoporosis, which is
Table 1: Baseline characteristics.
Overall
ppFEV1 (SD) 67± 23
BMI kg/m2 (SD) 22.3± 3.5
Age, years (SD) 33.1± 10
Males, n (%) 62 (50.4)
Females, n (%) 63 (49.6)
Pancreas insuﬃciency, n (%) 120 (97)
Homozygous F508del, n (%) 89 (71)
CF-related diabetes, n (%) 51 (41)
CF-related diabetes, duration in years (IQR) 10 (6–18)
Chronic infection, n (%) 101 (81)
Steroid inhalation therapy, n (%) 55 (44)
Additional D3 supplementation, n (%) 47 (38)
Proton pump inhibitors, n (%) 44 (35)
Spine BMD 1.145± 0.158
Femoral BMD 0.974± 0.197
T score −0.981± 1.260
Z score −0.748± 1.110
ppFEV1: percent predicted forced expiratory volume in 1 second; BMI: body
mass index; extra D3 supplementation: additional D3 supplementation on
top of routine supplementation; BMD: bone mineral density; T score:
lowest T score at any site for cases; Z score: lowest Z score at any site for
cases; IQR: interquartile range; SD: standard deviation.
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Table 2: Calcium metabolic and biochemical diﬀerences between groups.
Normal range Overall BMD within the normal range Osteoporosis p between groups
25OHD (n = 121) (>50 nmol/l) 49 (32–71) 49 (34–71) 32 (16–71) 0.39
Calcium (n = 125) (2.15–2.51mmol/l) 2.21 (2.12–2.31) 2.22 (2.13–2.32) 2.12 (2.02–2.28) 0.26
PTH (n = 125) (1.6–6.9 pmol/l) 2.12 (1.36–2.91) 2.12 (1.37–2.76) 2.13 (1.6–4.86) 0.18
Mg2+ (n = 117) (0.71–0.94mmol/l) 0.8 (0.75–0.84) 0.8 (0.76–0.84) 0.77 (0.7–0.87) 0.18
PH− (n = 117) (0.71–1.53mmol/l) 1.07 (0.96–1.18) 1.07 (0.96–1.16) 1.11 (0.94–1.29) 0.44
A phosphatase (n = 123) (35–105U/l) 94 (77–122) 89 (76–120) 112 (83–170) 0.11
Zink (n = 110) (10–19 μmol/l) 13 (11–14) 13 (11–15) 11 (9–13) 0.13
Albumin (N = 122) (36–48 g/l) 38 (34–42) 39 (34–42) 37 (30–39) 0.02
IgG (n = 121) (6.1–14.9 g/l) 11.2 (9–13.7) 11.2 (9.00–13.25) 12.00 (8.4–14.90) 0.46
hsCRP (n = 125) (<3.00mg/l) 2.34 (1.00–6.97) 2.10 (0.93–6.94) 4.52 (2.80–8.22) 0.04
Urea (n = 124) (3.2–8.1mmol/l) 4.7 (3.93–6.18) 4.70 (3.90–6.10) 5.00 (4.20–6.80) 0.84
Creatinine (n = 124) (60–105 μmol/l) 70 (60–83) 69 (60–81) 73 (63–104) 0.13
ALT (n = 123) (10–70U/l) 26 (19–39) 26 (19–42) 28 (19–31) 0.02
LDH (n = 122) (115–255U/l) 158 (142–176) 159 (142–179) 152 (140–170) 0.43
hbA1c (n = 122) (<48mmol/mol) 41 (36–53) 40 (36–49) 55 (40–78) 0.007
TSH (n = 122) (0.65–4.80× 10−3 IU/l) 1.85 (1.24–2.58) 1.87 (1.25–2.61) 1.81 (0.92–2.56) 0.90
All data presented as median and interquartile range (IQR). 25OHD: vitamin D; PTH: parathyroid hormone; Mg2+: magnesium; PH−: phosphate; A
phosphatase: alkaline phosphatase; IgG: immunoglobulin G; hsCRP: high-sensitive C-reactive protein; ALT: alanine aminotransferase; LDH: lactate
dehydrogenase; hbA1c: hemoglobin A1c; TSH: thyroid-stimulating hormone; m: milli; μ: micro; n: nano; pmol: picomol; l: liter; IU: international units; g: gram.
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Figure 1: Seasonal variation in calcium metabolic parameters.
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comparable to other CF cohorts [5]. Z scores were signiﬁ-
cantly lower compared to a healthy, age-matched population,
and bone density was independently associated with
ppFEV1, chronic infection, and female gender.
Consistent with previous ﬁndings, ppFEV1 was signif-
icantly associated with BMD [5, 6, 13, 14]. As well, BMI
and albumin were signiﬁcantly lower while CFRD and
chronic infection frequencies were signiﬁcantly higher in
osteoporotic patients compared to patients with BMD
values within the normal range. And patients homozygous
for the F508del mutation had signiﬁcant lower BMD com-
pared to patients bearing only one or no F508del mutation.
These ﬁndings all represent disease severity and progression
conﬁrming that clinical status is an important factor for
Table 3: Calcium metabolic parameters by vitamin D status.
Normal range Deﬁcient Insuﬃcient Replete p
Calcium (2.15–2.51mmol/l) 2.17 (0.16) 2.21 (0.14) 2.23 (0.17) 0.27
Phosphate (0.71–1.53mmol/l) 1.16 (0.2) 1.08 (0.16) 1.02 (0.16) 0.006
PTH (1.6–6.9 pmol/l) 3.5 (3.12) 2.18 (0.86) 2.10 (1.10) 0.001
Magnesium (0.71–0.94mmol/l) 0.80 (0.07) 0.80 (0.06) 0.79 (0.08) 0.34
Alkaline phosphatase (35–105U/l) 129.13 (87) 105.00 (43) 107.00 (65) 0.30
ANOVA p value. Values are displayed as mean (SD).
Table 4: Sex hormones in males and females.
Normal range Overall BMD within the normal range Osteoporosis p between groups
Males (n = 58)
FSH (<11 IU/l) 5.36 (3.07–9.18) 6.36 (3.09–10.62) 4.10 (2.96–5.45) 0.68
LH (1.7–8.6 IU/l) 4.89 (3.79–6.74) 5.22 (3.96–7.32) 4.29 (2.69–6.02) 0.71
Testosterone (8.6–29 nmol/l) 14.65 (10.47–17.79) 15.05 (11.32–18.13) 9.38 (9.02–12.07) 0.002
Estradiol (0.09–0.22 nmol/l) 0.09 (09–.0.11) 0.09 (0.09–0.12) 0.09 (0.09–0.11) 0.40
Females (n = 55)
FSH (1.9–20 IU/l) 5.04 (3.77–6.58) 4.82 (3.77–6.70) 5.12 (3.69–6.29) 0.51
LH (1.0–95.6 IU/l) 5.65 (2.65–8.81) 5.57 (2.61–8.92) 6.26 (2.10–7.97) 0.39
Testosterone (0.4–1.7 nmol/l) 0.83 (0.47–1.39) 0.81 (0.42–1.35) 1.39 (0.61–3.21) 0.61
Estradiol (0.05–1.46 nmol/l) 0.15 (0.11–0.33) 0.19 (0.11–0.35) 0.12 (0.09–0.13) 0.003
All data presented as median and interquartile range (IQR). FSH: follicle-stimulating hormone; LH: luteinizing hormone; n: nano; l: liter; IU: international
units.
Table 5: Diﬀerence in baseline characteristics between osteoporotic and nonosteoporotic groups.
BMD within the normal range
(N = 106)
Osteoporosis
(N = 19) p between groups
ppFEV1 (IQR) 70 (52–87) 44 (27–65) <0.001
BMI kg/m2 (IQR) 22.5 (20.4–24.5) 19.6 (18.8–20.7) <0.001
Age, years (IQR) 30 (24–39) 34 (25–47) 0.52
Males, n (%) 55 (52) 7 (37) 0.27
Females, n (%) 51 (48) 12 (63) —
Pancreas insuﬃciency, n (%) 101 (95) 19 (100) ns
Homozygous F508del, n (%) 74 (70) 16 (84) 0.38
CF-related diabetes, n (%) 43 (39) 8 (53) 0.03
CF-related diabetes, duration in years (IQR) 9 (6–16) 15 (10–25) 0.06
Chronic infection, n (%) 82 (77) 19 (100) 0.02
Steroid inhalation therapy, n (%) 52 (47) 3 (20) 0.06
Additional D3 supplementation, n (%) 36 (34) 11 (58) 0.05
Proton pump inhibitors, n (%) 41 (39) 2 (16) 0.07
ppFEV1: percent predicted forced expiratory volume in 1 second; BMI: body mass index; additional D3 supplementation: additional D3 supplementation in
addition to routine supplementation; BMD: bone mineral density; IQR: interquartile range.
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impaired bone strength in CF [13–16]. The fact that mean Z
score was signiﬁcantly below the average healthy mean also
justiﬁes more frequent monitoring of BMD in CF popula-
tions in order to identify patients at increased risk.
Cross-sectional studies in CF and other respiratory dis-
eases [17, 18] have observed ﬁndings similar to ours between
decreased BMD and lung function, but it is not yet deter-
mined, whether it is the decreasing lung function itself or
other factors induced by declining FEV1, which mediates
the decreased BMD. In CF, a suspected link between lung
function and decreasing BMD is systemic inﬂammation.
Studies have described associations between pulmonary
exacerbations, increased osteoclast maturation and activity
[19, 20], and increased levels of inﬂammatory cytokines
known to promote bone resorption, for example, IL-6, IL-1,
and TNFα [21, 22]. The signiﬁcant and independent associa-
tion of chronic infection with femoral Z score in our study
and the higher hsCRP levels in osteoporotic patients support
the relation between inﬂammation and bone loss.
The median 25OHD levels were considerably lower than
Endocrine Society [23] and CFF [24] recommendations, and
contrary to established pathogenetic understanding of
decreased bone strength, there was no diﬀerence in 25OHD
across between osteoporotic and nonosteoporotic groups.
Noteworthy is the diﬀerence between summer and winter
levels indicating that exposure to UVB radiation may be an
eﬀective way of increasing vitamin D levels bypassing malab-
sorption from the gut. The seasonal variation is also noted in
other CF studies [25, 26] and may explain why it is diﬃcult to
determine a link between BMD and 25OHD levels. CF
patients though, especially when chronically infected and
deteriorating in lung function, are subject to a heavy treat-
ment burden, and several studies of adherence to therapy in
CF have consistently shown that therapy compliance often
Table 6: Univariate regression between spine and femoral T and Z scores and biochemical and clinical parameters.
Spine Z score Femoral Z score Spine T score Femoral T score
B 95% CI B 95% CI B 95% CI B 95% CI
Albumin 0.03 (−0.01–0.07) ∗0.05 (0.01–0.09) ∗0.05 (0.002–0.09) ∗0.08 (0.03–0.12)
PTH −0.52 (−1.31–0.27) ∗−0.19 (−1.59 to −0.02) −0.69 (−1.46–0.28) ∗−0.23 (−0.36 to −0.09)
25OHD 0.001 (−0.01–0.01) 0.02 (−0.08–0.13) 0.04 (−0.07–0.16) 0.03 (−0.09–0.15)
Calcium 0.84 (−0.50–2.18) ∗1.36 (0.004–2.67) 1.41 (−0.06–2.88) ∗1.93 (0.41–3.47)
hbA1c ∗−0.25 (−0.44 to −0.05) ∗−0.38 (−0.57 to −0.18) ∗−0.35 (−0.56 to −0.13) ∗−0.46 (−0.69 to −0.26)
hsCRP −0.36 (−0.75–0.32) −0.62 (−1.01 to −0.23) −0.38 (−0.81–0.05) ∗−0.69 (−1.14 to −0.25)
ppFEV1 ∗∗0.02 (0.01–0.02) ∗∗0.03 (0.02–0.03) ∗∗0.02 (0.01–0.03) ∗∗0.03 (0.03–0.04)
BMI 0.05 (−0.01–0.11) ∗0.06 (0.003–0.12) ∗∗0.13 (0.07–0.2) ∗∗0.12 (0.05–0.20)
∗p < 0 05; ∗∗p < 0 001.
Table 7: Multivariate Linear Regression for spine and femoral T and Z score.
Variables B SE of B 95% CI of B β B SE of B 95% CI of B β
Femoral T score Femoral Z score
Female gender 0.407 0.23 -0.045 - 0.859 0.15 0.349 0.14 -0.075 - 0.775 0.14
BMI 0.056 0.04 -0.012 - 0.125 0.15 0.012 0.03 -0.052 - 0.076 0.04
ppFEV1 ∗∗0.027 0.01 0.017 - 0.038 0.46 ∗∗0.022 0.01 0.012 - 0.032 0.42
Chronic Infection ∗-0.643 0.26 -1.166 to -0.120 -0.18 ∗-0.617 0.25 -1.105 to -0.13 -0.20
Vitamin D -0.017 0.05 -0.112 - 0.078 0.06 -0.011 0.05 -0.100 - 0.078 -0.02
Estradiol -0.059 0.42 -0.891 - 0.773 -0.01 -0.110 0.40 -0.883 - 0.669 -0.02
HsCRP log10 -0.292 0.21 -0.705 - 0.12 -0.11 -0.30 -0.13 -0.681 - 0.089 -0.13
Spine T score Spine Z score
Female gender ∗0.598 0.23 0.133 – 1.062 0.23 ∗0.560 0.22 0.115 – 1.003 0.24
BMI ∗∗0.108 0.04 0.037 – 0.178 0.29 0.027 0.03 -0.047 – 0.094 0.08
ppFEV1 ∗∗0.015 0.01 0.004 – 0.026 0.26 ∗0.012 0.01 0.002 – 0.023 0.24
Chronic Infection ∗-0.633 0.27 -1.170 to -0.096 -0.19 ∗∗-0.724 0.30 -1.237 to –0.211 -0.24
Vitamin D 0.003 0.05 -0.094 – 0.101 0.01 0.000 0.06 -0.093 – 0.094 0.00
Estradiol 0.190 0.43 -0.664 – 1.044 0.04 0.18 0.41 -0.636 – 0.997 0.04
hsCRP log 10 -0.033 0.21 -0.457 – 0.391 -0.01 -0.046 0.20 -0.451 – 0.360 -0.02
∗p < 0 05. ∗∗p < 0 01. Vitamin D is square rooted and hsCRP log10 transformed. Model ﬁt: Femoral T score: R2 0.39, adj. R2 0.36, F(7/113)=10.71, p < 0 001.
Femoral Z score: R2 0.27, adj. R2 0.32, F(7/113)=7.61, p < 0 001. Spine T score: R2 0.31, adj. R2 0.26, F(7/113)=7.15, p < 0 001. Spine Z score: R2 0.22, adj.
R2 0.17, F(7/113)=4.58, p < 0 001.
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is as low as 50% of prescribed medications [27, 28]; this may
further obscure a relationship between prescribed vitamin D
doses and blood levels measured.
After all, our—as well as others’—ﬁndings [29–31] indi-
cate that the role of vitamin D in CF bone disease may be
minor compared to other complications negatively aﬀecting
bone mass such as clinical status and possibly inﬂammatory
bone loss.
That said, intervention studies investigating bone sta-
tus longitudinally have used inadequate ergocalciferol
(D2)/cholecalciferol (D3) doses of less than 3000 IU/day
[31], while at present, there is consensus that oral doses of
50,000 IU D3 weekly for at least eight weeks are likely needed
to signiﬁcantly increase 25OHD levels above 75nmol/l in
vitamin D-deﬁcient CF patients [8, 23, 32].
Interestingly, osteoporotic patients had higher prevalence
of CFRD and poorer glycemic control (hbA1c) compared to
patients with normal BMD, and there was a trend towards
longer duration of CFRD in the osteoporotic group. There
might be several ways in which CFRD contributes to CF bone
disease. A recent study demonstrated elevated levels of recep-
tor of advanced glycation end products (RAGE) and
advanced glycation end products (AGE) in CF patients with
CFRD compared to CF patients without CFRD and healthy
controls [33]. While RAGE can enhance bone resorption
through stimulation of proinﬂammatory cytokines and oxi-
dative stress species [34], AGE cross-linking in bone could
render CF bones more susceptible to fracture [35]. Further,
osteoblast function/formation could be aﬀected [36], as insu-
linopenia, which is present in CFRD, has been shown to
cause impaired fracture healing [37] and bone formation
deﬁcits [38] in rodent models. The importance of these
mechanisms in CF bone disease is yet to be determined.
Male patients had completely suppressed estradiol levels
in both the osteoporotic and nonosteoporotic group despite
estradiol being the most important sex hormone for bone
in males as well as females [39]. The seemingly low testoster-
one levels point to male hypogonadism, which in conjunc-
tion with the completely suppressed estradiol, indicate
possible sex hormone alterations, which should be investi-
gated further together with its possible impact on BMD in
CF males.
We acknowledge that there are limitations to our study.
We did not have reliable information about oral/intravenous
corticosteroid use which would have allowed evaluation of
systemic steroids on BMD in the cohort. However, these
are generally only used for intermittent worsening of CF
arthritis or treatment of allergic bronchopulmonary aspergil-
losis. Hypothetically, though, such repeated high-dose pred-
nisone in adolescence could have a negative impact on peak
bone mass accrual making a subgroup more susceptible to
loss of bone mass in adulthood.
Neither was it possible to measure free fractions of sex
hormones, obtain history of menstrual cycle or symptoms
of hypogonadism from patient records, preventing any ﬁnal
conclusions about sex hormones’ impact on CF bone status.
Finally, we did not have any radiographic data or patient
history to determine correlation between any osteoporotic
fractures and BMD, a relationship which is being questioned
over the recent years as peripheral quantitative computed
tomography scans have shown altered microarchitecture in
CF bone independently of BMD [40].
In conclusion, CF patients develop impaired BMD asso-
ciated with deteriorating clinical status. It is therefore impor-
tant to identify these individuals at risk and ensure regular
DXA scans and optimize treatment of modiﬁable risk factors
of osteoporosis. Although the skeleton is the body’s calcium
storage, there was little indication that alterations in calcium
metabolism signiﬁcantly impact bone status, despite median
vitamin D levels being well below recommended values.
Long-term high-dose vitamin D studies are needed to clarify
the role of 25OHD in CF bone disease and to which extent it
may have an eﬀect on BMD longitudinally. Sex hormonal
and dysglycemic impact on bone status should be investi-
gated further.
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